| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | METHOD FOR THE ENZYMATIC PRODUCTION OF 3-BUTEN-2-ONE | US14902565 | 2014-07-02 | US20160369306A1 | 2016-12-22 | Philippe Marliere; Maria Anissimova; Mathieu Allard |
| Described is a method for the production of 3-buten-2-one comprising the enzymatic conversion of 4-hydroxy-2-butanone into 3-buten-2-one by making use of an enzyme catalyzing 4-hydroxy-2-butanone dehydration, wherein said enzyme catalyzing 4-hydroxy-2-butanone dehydration is (a) a 3-hydroxypropiony-CoA dehydratase (EC 4.2.1.116), (b) a 3-hydroxybutyryl-CoA dehydratase (EC 4.2.1.55), (c) an enoyl-CoA hydratase (EC 4.2.1.17), (d) a 3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.59), (e) a crotonyl-[acyl-carrier-protein] hydratase (EC 4.2.1.58), (f) a 3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.60), (g) a 3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.61), (h) a long-chain-enoyl-CoA hydratase (EC 4.2.1.74), or (i) a 3-methylglutaconyl-CoA hydratase (EC 4.2.1.18). The produced 3-buten-2-one can be further converted into 3-buten-2-ol and finally into 1,3-butadiene. | ||||||
| 2 | Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tightened Gut Mucosal Barrier | US15772289 | 2016-09-08 | US20180312851A1 | 2018-11-01 | Dean Falb; Vincent M. Isabella; Jonathan W. Kotula; Paul F. Miller; Yves Millet; Adam Fisher |
| Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed. | ||||||
| 3 | BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER | US15301230 | 2016-03-02 | US20170128499A1 | 2017-05-11 | Dean Falb; Vincent M. Isabella; Jonathan W. Kotula; Paul F. Miller |
| Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed. | ||||||
| 4 | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier | US14998376 | 2015-12-22 | US20160206666A1 | 2016-07-21 | Dean Falb; Vincent M. Isabella; Jonathan W. Kotula; Paul F. Miller |
| Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed. | ||||||
| 5 | Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tighten Gut Mucosal Barrier | US15868487 | 2018-01-11 | US20180273956A1 | 2018-09-27 | Dean Falb; Vincent M. Isabella; Jonathan W. Kotula; Paul F. Miller |
| Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed. | ||||||
| 6 | Method for the enzymatic production of 3-buten-2-one | US14902565 | 2014-07-02 | US09850504B2 | 2017-12-26 | Philippe Marliere; Maria Anissimova; Mathieu Allard |
| Described is a method for the production of 3-buten-2-one comprising the enzymatic conversion of 4-hydroxy-2-butanone into 3-buten-2-one by making use of an enzyme catalyzing 4-hydroxy-2-butanone dehydration, wherein said enzyme catalyzing 4-hydroxy-2-butanone dehydration is (a) a 3-hydroxypropiony-CoA dehydratase (EC 4.2.1.116), (b) a 3-hydroxybutyryl-CoA dehydratase (EC 4.2.1.55), (c) an enoyl-CoA hydratase (EC 4.2.1.17), (d) a 3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.59), (e) a crotonyl-[acyl-carrier-protein] hydratase (EC 4.2.1.58), (f) a 3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.60), (g) a 3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.61), (h) a long-chain-enoyl-CoA hydratase (EC 4.2.1.74), or (i) a 3-methylglutaconyl-CoA hydratase (EC 4.2.1.18). The produced 3-buten-2-one can be further converted into 3-buten-2-ol and finally into 1,3-butadiene. | ||||||
| 7 | BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER | US15260319 | 2016-09-08 | US20170067065A1 | 2017-03-09 | Dean Falb; Vincent M. Isabella; Jonathan W. Kotula; Paul F. Miller; Yves Millet; Adam Fisher |
| Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed. | ||||||
| 8 | ３−ブテン−２−オンの酵素的製造のための方法 | JP2016522608 | 2014-07-02 | JP2016526382A | 2016-09-05 | マルリエール，フィリップ; アニシオバ，マリア; アラード，マテュー |
| 4−ヒドロキシ−2−ブタノン脱水を触媒する酵素を利用することによる4−ヒドロキシ−2−ブタノンから3−ブテン−2−オンへの酵素的変換を含む、3−ブテン−2−オンの製造のための方法であって、前記4−ヒドロキシ−2−ブタノン脱水を触媒する酵素が、(a)3−ヒドロキシプロピオニルCoA脱水酵素(EC4.2.1.116)、(b)3−ヒドロキシブチリルCoA脱水酵素(EC4.2.1.55)、(c)エノイルCoA加水酵素(EC4.2.1.17)、(d)3−ヒドロキシオクタノイル−[アシルキャリアータンパク質]脱水酵素(EC4.2.1.59)、(e)クロトニル−[アシルキャリアータンパク質]加水酵素(EC4.2.1.58)、(f)3−ヒドロキシデカノイル−[アシルキャリアータンパク質]脱水酵素(EC4.2.1.60)、(g)3−ヒドロキシパルミトイル−[アシルキャリアータンパク質]脱水酵素(EC4.2.1.61)、(h)長鎖エノイルCoA加水酵素(EC4.2.1.74)、または(i)3−メチルグルタコニルCoA加水酵素(EC4.2.1.18)である、3−ブテン−2−オンの製造のための方法を記載する。製造された3−ブテン−2−オンは、3−ブテン−2−オールに、最終的に1,3−ブタジエンにさらに変換することができる。 | ||||||
| 9 | METHOD FOR THE ENZYMATIC PRODUCTION OF 3-BUTEN-2-ONE | PCT/EP2014064102 | 2014-07-02 | WO2015000981A3 | 2015-02-19 | MARLIERE PHILIPPE; ANISSIMOVA MARIA; ALLARD MATHIEU |
| Described is a method for the production of 3-buten-2-one comprising the enzymatic conversion of 4-hydroxy-2-butanone into 3-buten-2-one by making use of an enzyme catalyzing 4-hydroxy-2-butanone dehydration, wherein said enzyme catalyzing 4-hydroxy-2-butanone dehydration is (a) a 3-hydroxypropiony-CoA dehydratase (EC 4.2.1.116), (b) a 3-hydroxybutyryl-CoA dehydratase (EC 4.2.1.55), (c) an enoyl-CoA hydratase (EC 4.2.1.17), (d) a 3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.59), (e) a crotonyl-[acyl-carrier-protein] hydratase (EC 4.2.1.58), (f) a 3-hydroxydecanoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.60), (g) a 3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.61 ), (h) a long-chain-enoyl-CoA hydratase (EC 4.2.1.74), or (i) a 3-methylglutaconyl-CoA hydratase (EC 4.2.1.18). The produced 3-buten-2-one can be further converted into 3-buten-2-ol and finally into 1,3-butadiene. | ||||||
QQ群二维码
意见反馈
意见反馈